Study Summary
This trial will test whether it's safe & effective to give Lutathera directly into the liver artery, compared to the standard approach of intravenous infusion in the arm.
- Neuroendocrine Tumors
- Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: 2 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
PRRT with 177Lu-DOTATATE
1 of 1
Experimental Treatment
10 Total Participants · 1 Treatment Group
Primary Treatment: 177Lu-DOTATATE · No Placebo Group · Phase < 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 11 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
Idaho | 100.0% |
How old are they?
65+ | 100.0% |
What portion of applicants met pre-screening criteria?
Did not meet criteria | 100.0% |
Frequently Asked Questions
Are there any vacancies available for this research endeavor?
"According to the clinicaltrials.gov database, this research effort is presently open for participants and was first announced on September 2nd 2020 with its latest update being January 19th 2022." - Anonymous Online Contributor
How many candidates does this trial have capacity for?
"Affirmative, the information hosted on clinicaltrials.gov elucidates that this study is currently recruiting participants; being originally posted on September 2nd 2020 and recently updated on January 19th 2022. A total of 10 enrollees are sought across a single site." - Anonymous Online Contributor
Could you provide a summary of prior research undertaken into the efficacy of 177Lu-DOTATATE?
"Currently, 23 active clinical trials are assessing the efficacy of 177Lu-DOTATATE, with one in its final phase. This treatment is being studied by researchers across 162 sites, particularly concentrated in Québec and Iowa." - Anonymous Online Contributor